Friday, November 22, 2024
11/22/2024
¿ DESCRIPTION (provided by applicant): Over a half billion individuals worldwide are infected with herpes simplex virus type 1 and/or type 2 (HSV-1 & HSV-2), which cause genital herpes. Most HSV-seropositive individuals are asymptomatic (ASYMP) and never have any recurrent herpetic disease. In contrast, a small proportion is symptomatic (SYMP), with frequent, often lifelong bouts of recurrent herpetic disease, a result of reactivation of latent HSV from sensory neurons of the dorsal root ganglia (DRG). Our long-term goal is to develop an immunotherapeutic vaccine to prevent virus reactivation from latency and protect against recurrent genital herpes disease. The most recent vaccine clinical trials that used HSV-2 glycoprotein D (gD) failed to protect despite inducing strong HSV-specific neutralizing antibodies. This proposal emphasizes two major gaps in knowledge: (1) The need to induce cell-mediated immune responses (in addition to humoral responses) for better protection. (2) The need to identify novel herpes T cell antigens (Ags) to be incorporated into next-generation HSV vaccines. A critical role for HSV- specific sensory ganglia-resident CD8+ T cells in aborting HSV reactivation has been established, and the involvement of CD4+ T cells is gaining wider acceptance. Paradoxically, HSV-specific genital tract (GT)- resident CD4+ and CD8+ T-cells are also involved in herpes pathogenicity. The Ag specificities of protective and pathogenic CD4+ and CD8+ T-cells remain to be elucidated. Our recent published and preliminary data demonstrate that: (A) CD4+ and CD8+ T-cells from HSV-seropositive SYMP and ASYM individuals differ in their HSV Ag-specificities, phenotype, and function. (B) Immunization of novel susceptible Human Leukocyte Antigen- (HLA-) A/DR double transgenic mice (HLA Tg mice) with ASYMP Ags, but not SYMP Ags, induced a strong T cell-dependent protective immunity against genital herpes. Building on the above published and preliminary data in both humans and HLA Tg mice, we hypothesize that: (1) CD4+ and CD8+ T-cells specific to HSV Ags can be either protective or pathogenic, and (2) A vaccine strategy that can boost the number and/or function of DRG-resident protective CD4+ and CD8+ T cells will prevent or reduce virus reactivation and, hence, protect against recurrent genital herpes. Our Specific Aims are: Aim 1: To confirm the hypothesis that there is a set of HSV Ags that are recognized mostly by CD4+ and CD8+ T cells from ASYMP individuals and a different set of Ags that are recognized mostly by CD4+ and CD8+ T cells from SYMP individuals. Aim 2: To test the hypothesis that immunization of HLA double Tg mice with immunodominant ASYMP Ags, but not with SYMP Ags, will induce DRG-resident CD4+ and CD8+ T cells, and protect against genital herpes infection and disease. Successful completion of the proposed work should help build a strong foundation toward developing an effective genital herpes vaccine.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
